Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI

Study identifier:D419MC00006

ClinicalTrials.gov identifier:NCT05826366

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

Specific use-results study of IMJUDO Intravenous Infusion 25mg / IMFINZI Intravenous Infusion 120mg,500mg All Patient Investigation in patients with unresectable advanced or recurrent non-small cell lung cancer

Medical condition

Carcinoma, Non-Small-Cell Lung

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

296

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 02 Jun 2023
Estimated Primary Completion Date: 16 Nov 2025
Estimated Study Completion Date: 16 Nov 2025

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria